141 related articles for article (PubMed ID: 29207486)
1. Superior Stability of Hydroxysafflor Yellow A in Xuebijing Injection and the Associated Mechanism.
Pu W; Zhang H; Wang M; Liu Y; Sun L; Ren X
Molecules; 2017 Dec; 22(12):. PubMed ID: 29207486
[TBL] [Abstract][Full Text] [Related]
2. Plasma and cerebrospinal fluid pharmacokinetics of hydroxysafflor yellow A in patients with traumatic brain injury after intravenous administration of Xuebijing using LC-MS/MS method.
Sheng C; Peng W; Xia Z; Wang Y
Xenobiotica; 2020 May; 50(5):545-551. PubMed ID: 31524030
[TBL] [Abstract][Full Text] [Related]
3. Determination of hydroxysafflor yellow A in biological fluids of patients with traumatic brain injury by UPLC-ESI-MS/MS after injection of Xuebijing.
Guo Y; Wang Y; Huang X; Lv H; Fan R; Huang W; Gan P; Liu W; Yan K; Xia Z; Liu J
Biomed Chromatogr; 2014 Aug; 28(8):1090-5. PubMed ID: 24535782
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological Actions, Molecular Mechanisms, Pharmacokinetic Progressions, and Clinical Applications of Hydroxysafflor Yellow A in Antidiabetic Research.
Zhang X; Shen D; Feng Y; Li Y; Liao H
J Immunol Res; 2021; 2021():4560012. PubMed ID: 34938814
[TBL] [Abstract][Full Text] [Related]
5. A novel oral preparation of hydroxysafflor yellow A base on a chitosan complex: a strategy to enhance the oral bioavailability.
Ma GN; Yu FL; Wang S; Li ZP; Xie XY; Mei XG
AAPS PharmSciTech; 2015 Jun; 16(3):675-82. PubMed ID: 25511808
[TBL] [Abstract][Full Text] [Related]
6. Paeoniflorin and Hydroxysafflor Yellow A in Xuebijing Injection Attenuate Sepsis-Induced Cardiac Dysfunction and Inhibit Proinflammatory Cytokine Production.
Wang XT; Peng Z; An YY; Shang T; Xiao G; He S; Chen X; Zhang H; Wang Y; Wang T; Zhang JH; Gao X; Zhu Y; Feng Y
Front Pharmacol; 2020; 11():614024. PubMed ID: 33986658
[TBL] [Abstract][Full Text] [Related]
7. Molecular dynamics simulation integrating the inhibition kinetics of hydroxysafflor yellow A on α-glucosidase.
Xu Y; Lee J; Park YD; Yang JM; Zheng J; Zhang Q
J Biomol Struct Dyn; 2018 Mar; 36(4):830-840. PubMed ID: 28264629
[TBL] [Abstract][Full Text] [Related]
8. Effects of hydroxysafflor yellow A on the activity and mRNA expression of four CYP isozymes in rats.
Xu RA; Xu ZS; Ge RS
J Ethnopharmacol; 2014 Feb; 151(3):1141-1146. PubMed ID: 24373810
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic profiles of hydroxysafflor yellow A following intravenous administration of its pure preparations in healthy Chinese volunteers.
Li CY; Yin JG; Zhang J; Wang XX; Xu MJ; Liu F; Zou JD; Ju WZ
J Ethnopharmacol; 2015 Mar; 162():225-30. PubMed ID: 25576896
[TBL] [Abstract][Full Text] [Related]
10. Enhancing effect of Labrafac Lipophile WL 1349 on oral bioavailability of hydroxysafflor yellow A in rats.
Wang S; Sun M; Ping Q
Int J Pharm; 2008 Jun; 358(1-2):198-204. PubMed ID: 18417306
[TBL] [Abstract][Full Text] [Related]
11. Hydroxysafflor yellow A promotes neovascularization and cardiac function recovery through HO-1/VEGF-A/SDF-1α cascade.
Wei G; Yin Y; Duan J; Guo C; Zhu Y; Wang Y; Xi M; Wen A
Biomed Pharmacother; 2017 Apr; 88():409-420. PubMed ID: 28122306
[TBL] [Abstract][Full Text] [Related]
12. Hydroxysafflor yellow A inhibits the proliferation, migration, and invasion of colorectal cancer cells through the PPARγ/PTEN/Akt signaling pathway.
Su D; Lv C
Bioengineered; 2021 Dec; 12(2):11533-11543. PubMed ID: 34889713
[TBL] [Abstract][Full Text] [Related]
13. Hydroxysafflor yellow A (HSYA) from flowers of Carthamus tinctorius L. and its vasodilatation effects on pulmonary artery.
Bai Y; Lu P; Han C; Yu C; Chen M; He F; Yi D; Wu L
Molecules; 2012 Dec; 17(12):14918-27. PubMed ID: 23519263
[TBL] [Abstract][Full Text] [Related]
14. Solid lipid nanoparticles as carriers for oral delivery of hydroxysafflor yellow A.
Zhao B; Gu S; Du Y; Shen M; Liu X; Shen Y
Int J Pharm; 2018 Jan; 535(1-2):164-171. PubMed ID: 29107614
[TBL] [Abstract][Full Text] [Related]
15. Identification of the major constituents in Xuebijing injection by HPLC-ESI-MS.
Huang H; Ji L; Song S; Wang J; Wei N; Jiang M; Bai G; Luo G
Phytochem Anal; 2011; 22(4):330-8. PubMed ID: 21500296
[TBL] [Abstract][Full Text] [Related]
16. Hydroxysafflor yellow A inhibits IL-1β-induced release of IL-6, IL-8, and MMP-1 via suppression of ERK, NF-κB and AP-1 signaling in SW982 human synovial cells.
Cheng BF; Gao YX; Lian JJ; Guo DD; Wang L; Wang M; Yang HJ; Feng ZW
Food Funct; 2016 Nov; 7(11):4516-4522. PubMed ID: 27713966
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic Study on Protocatechuic Aldehyde and Hydroxysafflor Yellow A of Danhong Injection in Rats with Hyperlipidemia.
Zhou J; Li M; Jin W; Li X; Fan H; Zhang Y
Pharmacology; 2018; 102(3-4):154-160. PubMed ID: 30045035
[TBL] [Abstract][Full Text] [Related]
18. Hydroxysafflor yellow A attenuate lipopolysaccharide-induced endothelium inflammatory injury.
Jin M; Sun CY; Zang BX
Chin J Integr Med; 2016 Jan; 22(1):36-41. PubMed ID: 26015073
[TBL] [Abstract][Full Text] [Related]
19. Hydroxysafflor yellow a inhibits lipopolysaccharide-induced inflammatory signal transduction in human alveolar epithelial A549 cells.
Song L; Zhu Y; Jin M; Zang B
Fitoterapia; 2013 Jan; 84():107-14. PubMed ID: 23160090
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of effects of Xuebijing injection and its component hydroxysafflor yellow A on coagulation and survival rates of septic rats].
Ren C; Yao R; Wang L; Liu Q; Wu Y; Dong N; Yao Y
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Oct; 33(10):1198-1202. PubMed ID: 34955128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
